Payment overview · 2025
General Payments
$131.07
1 reported records · 1 companies
Healthcare provider profile · identity verified
Peter R Harnish, MD
Allopathic & Osteopathic Physicians|Family Medicine · MADISON, WI · NPI 1194777599
Verified facts
What the public records show
CMS Open Payments records show Peter R Harnish, MD received $131.07 in general payments during 2025 across 1 reported records.
BridgeBio Pharma, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $131.07 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $131.07 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $131.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 651 | 170 |
| Omeprazole | Omeprazole | 372 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 55 |
| Metformin Hcl Er | Metformin Hcl | 221 | 54 |
| Lisinopril | Lisinopril | 205 | 61 |
| Simvastatin | Simvastatin | 196 | 54 |
| Enalapril Maleate | Enalapril Maleate | 193 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 45 |
| Metformin Hcl | Metformin Hcl | 158 | 37 |
| Gabapentin | Gabapentin | 153 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 35 |
| Furosemide | Furosemide | 138 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 38 |
| Sertraline Hcl | Sertraline Hcl | 127 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 115 | 27 |
| Potassium Chloride | Potassium Chloride | 110 | 31 |
| Losartan Potassium | Losartan Potassium | 103 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 86 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 42 |
| Trazodone Hcl | Trazodone Hcl | 83 | 25 |
| Benazepril Hcl | Benazepril Hcl | 82 | 22 |
| Allopurinol | Allopurinol | 79 | 21 |
| Warfarin Sodium | Warfarin Sodium | 75 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 16 |
| Glipizide Er | Glipizide | 64 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 11 |
| Eliquis | Apixaban | 57 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 11 |
| Bupropion Xl | Bupropion Hcl | 55 | 12 |
| Alendronate Sodium | Alendronate Sodium | 51 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Carvedilol | Carvedilol | 48 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | suppressed |
| Famotidine | Famotidine | 46 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 13 |
| Ozempic | Semaglutide | 43 | suppressed |
| Atenolol | Atenolol | 42 | 11 |
| Montelukast Sodium | Montelukast Sodium | 42 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 22 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | 11 |
| Baclofen | Baclofen | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 15 |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 20 |
| Glipizide | Glipizide | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 13 |
| Diazepam | Diazepam | 27 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Nexium | Esomeprazole Magnesium | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Meloxicam | Meloxicam | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 18 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Prednisone | Prednisone | 15 | 11 |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $131.07 · 1 records | BridgeBio Pharma, Inc. | Attruby | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error